CN114949044A - Antiviral traditional Chinese medicine composition and application thereof - Google Patents
Antiviral traditional Chinese medicine composition and application thereof Download PDFInfo
- Publication number
- CN114949044A CN114949044A CN202110199421.1A CN202110199421A CN114949044A CN 114949044 A CN114949044 A CN 114949044A CN 202110199421 A CN202110199421 A CN 202110199421A CN 114949044 A CN114949044 A CN 114949044A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- parts
- medicine composition
- viruses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 18
- 241000700605 Viruses Species 0.000 claims abstract description 39
- 229940079593 drug Drugs 0.000 claims abstract description 18
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 13
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 13
- 206010057190 Respiratory tract infections Diseases 0.000 claims abstract description 13
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 12
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 12
- 244000248416 Fagopyrum cymosum Species 0.000 claims abstract description 11
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 11
- 235000011477 liquorice Nutrition 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract 3
- 238000002360 preparation method Methods 0.000 claims description 23
- 239000000443 aerosol Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 241000576429 Forsythia suspensa Species 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 21
- 230000003612 virological effect Effects 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 239000000645 desinfectant Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 37
- 239000000243 solution Substances 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 239000000284 extract Substances 0.000 description 23
- 239000000463 material Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 241001570521 Lonicera periclymenum Species 0.000 description 10
- 238000012423 maintenance Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 229940126680 traditional chinese medicines Drugs 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 229960000329 ribavirin Drugs 0.000 description 5
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 231100000816 toxic dose Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000725643 Respiratory syncytial virus Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229940090044 injection Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 3
- 241000709687 Coxsackievirus Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000709661 Enterovirus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229960004150 aciclovir Drugs 0.000 description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 231100001274 therapeutic index Toxicity 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 244000167230 Lonicera japonica Species 0.000 description 2
- 235000017617 Lonicera japonica Nutrition 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- -1 decoction Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 208000020017 viral respiratory tract infection Diseases 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000208828 Caprifoliaceae Species 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 244000035851 Chrysanthemum leucanthemum Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241001660870 Cyrtomium Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000555712 Forsythia Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241001500350 Influenzavirus B Species 0.000 description 1
- 241000334154 Isatis tinctoria Species 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000100289 Lonicera confusa Species 0.000 description 1
- 241000173699 Lonicera dasystyla Species 0.000 description 1
- 241001170080 Lonicera hypoglauca Species 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000246044 Sophora flavescens Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 206010047482 Viral upper respiratory tract infection Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 229940108553 acyclovir injection Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000005560 droplet transmission Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000009891 weiqi Substances 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an antiviral traditional Chinese medicine composition which can be used for preparing a medicine for resisting viruses or preventing and treating viral diseases (particularly respiratory tract infection mainly caused by viruses). The traditional Chinese medicine composition follows the theoretical formula of traditional Chinese medicine and is prepared from the following raw materials in parts by weight: 1-25 parts of radix sophorae flavescentis, 1-25 parts of wild buckwheat rhizome and leaf, 1-25 parts of liquorice, 1-25 parts of honeysuckle, 1-25 parts of scutellaria baicalensis and 1-25 parts of fructus forsythiae. The traditional Chinese medicine composition has the obvious effect of inhibiting common viruses which can cause respiratory tract infection, so that the traditional Chinese medicine composition can be used for preparing antiviral medicines or medicines for preventing and treating viral diseases (particularly respiratory tract infection mainly caused by viruses), disinfectants and the like. The invention also relates to the medical application of the traditional Chinese medicine composition.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines and the field of health maintenance, in particular to a traditional Chinese medicine composition with antiviral effect and viral disease prevention and treatment effect, and particularly with the effect of preventing and treating respiratory tract infection mainly caused by viruses. In addition, the invention also relates to the medical application and the health maintenance application of the traditional Chinese medicine composition.
Background
Many viruses are pathogens that cause common infectious diseases, including rabies, smallpox, polio, hepatitis, yellow fever, immunodeficiency, encephalitis, respiratory infections, influenza, and the like, and are extremely infectious and dangerous. Such as rubella and cytomegalovirus, can cause congenital abnormalities, and tumor viruses can cause tumors in humans and animals. The main pathogens of the common cold are rhinoviruses, and then parainfluenza viruses, adenoviruses, echoviruses, coxsackieviruses, respiratory syncytial viruses and the like, which are often easy to be combined with bacterial infection. Influenza (influenza for short) is an acute respiratory infectious disease caused by influenza virus, pathogens are influenza virus A, influenza virus B and influenza virus C3, the influenza virus has acute high fever, hypodynamia, general muscular soreness and mild respiratory symptoms clinically through droplet transmission, and pneumonia is easily complicated by middle-aged people and patients with chronic respiratory diseases or heart diseases. Influenza viruses, particularly type a, are highly variable and often cause outbreaks, epidemics or pandemics. It can be said that due to the severe disturbance of the natural environment, the rapid variation of viruses, and the unscientific eating of wild animals by human beings, new viral diseases, especially the outbreak and prevalence of respiratory tract infection epidemic caused by viruses, are increasing, and the human society faces a great threat. At present, most of domestic and foreign western medicines adopt ribavirin, chloroquine, redciclovir and the like for treating rhinovirus, coronavirus and the like, but the effect is very limited and the toxic and side effects are very large. Because of the rapid spread, rapid mutation, high drug resistance of many viruses and the continuous emergence of new viruses, the research and development of drugs and vaccines require a long period, so that the prevention and treatment of viral diseases often lack specific means, and the research and development of drugs for preventing and treating viral diseases, particularly respiratory tract infection mainly caused by viruses, are urgently needed.
The traditional Chinese medicine has the comprehensive effects of inhibiting virus replication, regulating the immune function, improving blood circulation, relieving fever and pain, resisting bacteria and diminishing inflammation and the like, can play a role in multiple aspects, and has the advantages of low drug resistance, less adverse reaction and side effect and the like. The existing research shows that the action mechanism is as follows: some heat-clearing and detoxifying traditional Chinese medicines have direct antiviral effects, such as cyrtomium rhizome, honeysuckle, wild chrysanthemum flower, dyers woad leaf and the like; some heat-clearing and detoxifying Chinese herbal medicines have the effects of inducing interferon production in a human body, regulating the immunity of the human body, inhibiting virus replication, and improving the lung ventilation function and microcirculation, so that the condition of a patient is relieved, the course of disease is shortened, and the death rate is reduced. In a word, the traditional Chinese medicine has unique advantages and broad prospects in the aspect of preventing and treating viral diseases, particularly viral respiratory tract infection. The traditional Chinese medicine prescription is a main form of clinical application of the traditional Chinese medicine, can play a synergistic effect through the compatibility and combination of different traditional Chinese medicines, and plays a role through multiple ways and multiple target points. Because of various Chinese medicines, the Chinese medicine can be determined only by searching good Chinese medicine formula and investing a great deal of energy for screening and verification, and is a focus of attention in academia.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition with antiviral effect and a traditional Chinese medicine composition with the effect of preventing and treating viral diseases, in particular to a traditional Chinese medicine composition capable of preventing and treating respiratory tract infection mainly caused by viruses, and provides the medical and health maintenance application of the traditional Chinese medicine composition.
Because the clinical application form of the traditional Chinese medicine is mainly to select a plurality of traditional Chinese medicines to form a compound, which is also the advantage of the traditional Chinese medicine in preventing and treating viral diseases, the demand for good traditional Chinese medicine formula is very urgent. However, because of a large variety of medicines, the screening of good traditional Chinese medicine formula has large workload and great difficulty. The inventor is engaged in the traditional Chinese medicine research for a long time, aiming at the etiology and pathogenesis analysis of common viral respiratory tract infection under the guidance of the theory of traditional Chinese medicine, and through in vitro and animal tests and clinical verification, finally finds out the antiviral traditional Chinese medicine composition with better curative effect, and can prepare the antiviral traditional Chinese medicine composition into a proper dosage form for directly inhibiting viruses or preventing and treating viral diseases, in particular to preventing and treating respiratory tract infection mainly caused by viruses. The traditional Chinese medicine formula mainly comprises radix sophorae flavescentis, wild buckwheat rhizome and leaf, liquorice, honeysuckle, scutellaria baicalensis and fructus forsythiae. Wherein radix Sophorae Flavescentis is dried root of Sophora flavescens Ait, bitter and cold. It has effects of clearing heat, eliminating dampness, killing parasite, and promoting urination, and is suitable for heart, liver, stomach, large intestine, and bladder channels. The stem and leaf of rhizoma Fagopyri Dibotryis (D.Don) Hara is stem and leaf of rhizoma Fagopyri Dibotryis (D.Don) Hara of Polygonaceae, has bitter, pungent and cool nature, and has effects of clearing heat and detoxicating, invigorating spleen and promoting diuresis, dispelling pathogenic wind and dredging collaterals. The licorice is the dry root of Glycyrrhiza uralensis Fisch, Glycyrrhiza inflata Bat or Glycyrrhiza glabra L of Leguminosae, has sweet and flat nature and flavor, and has the effects of tonifying spleen and qi, clearing away heat and toxic materials, eliminating phlegm and stopping cough, relieving spasm and pain, and harmonizing the effects of the other drugs. The honeysuckle is a dried flower bud or a flower with an initial bloom of Lonicera japonica Thunb, Lonicera hypoglauca Miq, Lonicera confusa DC or Lonicera dasystyla Rehd of Lonicera japonica of Caprifoliaceae, has sweet and cold properties and tastes sweet and cold, enters lung, heart and stomach meridians, and has the effects of clearing heat and removing toxicity, and cooling and dispersing wind heat. The Scutellariae radix is dried root of Scutellaria baicalensis Georgi of Labiatae, and is bitter in taste and cold in nature, and enters lung, gallbladder, spleen, large intestine and small intestine meridians. Clear heat and dry dampness, purge fire and remove toxicity. Fructus forsythiae is dry fruit of Vahl of Forsythia subsensis (Thunb.) of Oleaceae, is bitter in taste and slightly cold, enters lung, heart and small intestine channels, and has effects of clearing away heat and toxic materials, relieving swelling and resolving hard mass. Generally, the prescription has the effects of clearing away heat and toxic materials, ventilating and smoothing lung, reducing phlegm and harmonizing ying and weiqi, and can be clinically used for resisting viruses such as influenza virus, rhinovirus, coronavirus, parainfluenza virus, respiratory syncytial virus, adenovirus, coronavirus and the like, or preventing and treating diseases caused by the viruses, particularly respiratory infection. In consideration of the factors of market circulation, storage and the like of the traditional Chinese medicines, the traditional Chinese medicines applied in clinic are mostly dry products. If the fresh-keeping effect can be well achieved without rotting, the traditional Chinese medicine composition adopts the corresponding fresh products of the traditional Chinese medicines in the formula, and is also feasible and even better in effect.
According to an embodiment, the antiviral traditional Chinese medicine composition provided by the invention is prepared from the following raw material medicines in parts by weight: 1-25 parts of radix sophorae flavescentis, 1-25 parts of wild buckwheat rhizome and leaf, 1-25 parts of liquorice, 1-25 parts of honeysuckle, 1-25 parts of scutellaria baicalensis and 1-25 parts of fructus forsythiae. Preferably: 1 part of radix sophorae flavescentis, 1 part of wild buckwheat rhizome and leaf, 1 part of liquorice, 1 part of honeysuckle, 1 part of scutellaria baicalensis and 1 part of forsythia suspensa.
The traditional Chinese medicine composition can be prepared by extracting each single medicine by adopting a proper solvent and then mixing, or can be prepared by mixing each single medicine, extracting by adopting a proper solvent, adjusting to a specified concentration or drying and then using. The extraction solvent can be water or 5-95% ethanol water solution, or methanol, preferably water or 25-75% ethanol water solution. If the extract is used as a decoction, water is preferably used as a solvent for extraction; when used as another preparation, a 10% to 50% ethanol aqueous solution is preferable, and a 25% ethanol aqueous solution is most preferable, and water may be used as a solvent.
The traditional Chinese medicine composition (liquid, extract and powder) can be prepared into various oral, injection and external preparations by adopting the conventional preparation technology with the auxiliary material carrier which is acceptable in pharmacy, such as common formulations of aerosol, decoction, tablets, capsules, granules, mixture and the like, and can be applied to places or people in need in oral, rectal or parenteral, nasal inhalation, atomized inhalation and spraying modes. The pharmaceutically acceptable auxiliary material carrier refers to a conventional pharmaceutical carrier in the pharmaceutical field, such as: diluents, excipients such as water, etc., fillers such as starch, sucrose, etc.; binders such as cellulose derivatives, alginates, gelatin, and polyvinylpyrrolidone; humectants such as glycerol; disintegrating agents such as agar, calcium carbonate and sodium bicarbonate; absorption promoters such as quaternary ammonium compounds; surfactants such as cetyl alcohol; adsorption carriers such as kaolin and bentonite; lubricants such as talc, calcium and magnesium stearate, and polyethylene glycol, etc.; propellants such as freon, hydrocarbons (propane, n-butane, isobutane); cosolvents such as propylene glycol, glycerol, ethanol, etc. In addition, other adjuvants such as flavoring agent, sweetener, etc. can be added for the preparation.
Experimental studies of the following examples of the present invention show that: the Chinese medicinal composition has the pharmacological action of remarkably inhibiting common viruses which can cause respiratory tract infection. The traditional Chinese medicine (medicinal plant) raw materials selected by the traditional Chinese medicine composition are mainly medicinal and edible varieties, have no toxic or side effect, high safety and low cost, and have remarkable advantages. Because viral upper respiratory tract infection is frequent and a specific prevention and treatment means is lacked, the traditional Chinese medicine composition has a good application prospect.
Detailed Description
The following detailed description of the present invention will be provided in conjunction with examples, which are to be construed as merely illustrative, and not limitative of the remainder of the disclosure. Various changes and modifications may be effected therein by one skilled in the art, and such equivalent changes and modifications also fall within the scope of the invention as defined in the appended claims.
Example 1 preparation of extract
Weighing 100g of radix sophorae flavescentis, 25g of stem and leaf of wild buckwheat rhizome, 10g of liquorice, 10g of honeysuckle, 10g of scutellaria baicalensis and 10g of fructus forsythiae respectively, adding 25% ethanol aqueous solution which is 10 times of the total weight of the medicinal materials, carrying out hot reflux extraction for 2 times, carrying out 1 hour each time, combining the extracting solutions, concentrating, and adjusting the concentration with distilled water to be equal to the concentration of the crude drug to be 1.0 g/mL. The extractive solution can be directly used as decoction or intermediate, and can be processed into appropriate dosage forms by adjusting concentration according to preparation requirement and adding appropriate adjuvants.
Example 2 preparation of extract
Weighing 25g of radix sophorae flavescentis, 25g of wild buckwheat rhizome and leaf, 100g of liquorice, 25g of honeysuckle, 100g of scutellaria baicalensis and 5g of fructus forsythiae respectively, adding 25% ethanol aqueous solution which is 10 times of the total weight of the medicinal materials, carrying out hot reflux extraction for 2 times, carrying out 1 hour each time, combining extracting solutions, concentrating, and adjusting the concentration by using distilled water to be equal to the concentration of the crude drug to be 1.0 g/mL. The extractive solution can be directly used as decoction or intermediate, and can be processed into appropriate dosage forms by adjusting concentration according to preparation requirement and adding appropriate adjuvants.
Example 3 preparation of extract
Weighing 5g of radix sophorae flavescentis, 5g of fagopyrum dibotrys stem and leaf, 50g of liquorice, 100g of honeysuckle, 25g of scutellaria baicalensis and 25g of fructus forsythiae respectively, adding 25% ethanol aqueous solution which is 10 times of the total weight of the medicinal materials, carrying out hot reflux extraction for 2 times, carrying out 1 hour each time, combining extracting solutions, concentrating, and adjusting the concentration with distilled water to be equal to the concentration of the crude drug to be 1.0 g/mL. The extractive solution can be directly used as decoction or intermediate, and can be processed into appropriate dosage forms by adjusting concentration according to preparation requirement, adding appropriate adjuvants.
Example 4 preparation of extract solution
Weighing 25g of radix sophorae flavescentis, 100g of fagopyrum dibotrys stem and leaf, 10g of liquorice, 50g of honeysuckle, 10g of scutellaria baicalensis and 5g of fructus forsythiae respectively, adding 25% ethanol aqueous solution which is 10 times of the total weight of the medicinal materials, carrying out hot reflux extraction for 2 times, carrying out 1 hour each time, combining extracting solutions, concentrating, and adjusting the concentration with distilled water to be equal to the concentration of the crude drug to be 1.0 g/mL. The extractive solution can be directly used as decoction or intermediate, and can be processed into appropriate dosage forms by adjusting concentration according to preparation requirement, adding appropriate adjuvants.
Example 5 preparation of extract
Weighing 5g of radix sophorae flavescentis, 5g of wild buckwheat rhizome and leaf, 5g of liquorice, 5g of honeysuckle, 5g of scutellaria baicalensis and 5g of fructus forsythiae respectively, adding 25% ethanol aqueous solution which is 10 times of the total weight of the medicinal materials, carrying out hot reflux extraction for 2 times, carrying out 1 hour each time, combining extracting solutions, concentrating, and adjusting the concentration by using distilled water to be equal to the concentration of the crude drug to be 1.0 g/mL. The extractive solution can be directly used as decoction or intermediate, and can be processed into appropriate dosage forms by adjusting concentration according to preparation requirement, adding appropriate adjuvants.
EXAMPLE 6 preparation of granules
The extract prepared in any one of embodiments 1 to 5 is concentrated and dried to obtain an extract, 20g of the extract is taken, 40g of dextrin is added, the extract is uniformly mixed, a proper amount of 60% ethanol is added to prepare a soft material, the soft material is sieved by a 24-mesh sieve to be granulated, the dry material is dried at 50 ℃ for 2 hours, the dry granules are sieved by a 30-mesh sieve to be granulated, and the obtained product is subpackaged.
EXAMPLE 7 preparation of capsules
The extract prepared in any one of embodiments 1 to 5 is concentrated and dried to obtain an extract, 20g of the extract is taken, 40g of dextrin is added, the mixture is uniformly mixed, a proper amount of 60% ethanol is added to prepare a soft material, the soft material is sieved by a 24-mesh sieve and granulated, the granulation is carried out at 50 ℃ for 2 hours, and the granules are dried and filled into capsules.
Example 8 preparation of mixture/oral liquid/syrup
The extract prepared in any one of embodiments 1 to 5 is concentrated, and then added with a suitable pharmaceutical excipient (white sugar, honey, phenylpropionic acid, ethylparaben, or the like) to adjust the concentration, thereby preparing a mixture, an oral liquid, or a syrup.
EXAMPLE 9 preparation of Aerosol
The extract prepared in any one of embodiments 1 to 5 is added with ethanol, essence, preservative and the like, the concentration is adjusted to 1 to 100mg/mL, and the mixture is filled into an aerosol bottle by taking propane and butane as propellants to prepare aerosol.
Example 10 determination of antiviral Activity of the Chinese medicinal composition of the present invention
Purpose of the experiment
The inhibiting effect of the traditional Chinese medicine composition on the common viruses causing respiratory tract infection is observed.
2 materials of experiment
2.1 reagents
DMEM medium (TBD10565, the balance of Tianjin, the world), double antibody (streptomycin mixed liquor, lot: BL-XB-0197, Boguan), phosphate buffer solution (PBS, PB2004Y, Tianjin sea), fetal bovine serum (FBS, 10099-141, Gibco USA), EDTA-0.25% pancreatin (BL-XB-0168, Boguan), thiazole blue dye solution (MTT, BL-SJ-0717, Boguan), ribavirin injection (Chengxin pharmaceutical industry GmbH, 1410206811); acyclovir for injection (Hubei noon pharmaceutical Co., Ltd., 1704031).
2.2 instruments
A two-beam ultraviolet-visible spectrophotometer (model TU-1901, Beijing Pujingyo general instruments, Inc.), a CKX-41 type inverted microscope (Olympus, Japan); HFsafe-1200TE type biosafety cabinet, MCO-15AC type CO 2 Cell constant temperature incubators (SANYO Electric biological co.ltd.japan), a TGL16M model bench top multitube automatic balance centrifuge (altin, shanghai), a BT25S electronic balance (one ten-thousandth, Sartorius, germany).
2.3 cell and Virus strains
Human malignant embryonic rhabdomyosarcoma cells (RD cells), rhesus embryonic kidney cells (MA104 cells), and human laryngeal carcinoma epithelial cells (Hep2 cells) were purchased from Shanghai Biomedicine science and technology, Inc. Hand-foot-and-mouth virus (EV71), herpes simplex virus type 1 (HSV-1), Respiratory Syncytial Virus (RSV), Coxsackie virus type B3 (CV-B3) and Coxsackie virus type B5 (CV-B5) were provided by the institute of basic medicine, college of medical sciences, Shandong province. Cell culture solution: taking 450mL of DMEM medium, adding 50mL of fetal bovine serum and 2mL of double antibody, mixing uniformly, and refrigerating at 4 ℃. Cell maintenance solution: the cell culture solution was diluted 5-fold with DMEM medium.
3 Experimental methods
3.1 preparation of test drug solutions
The extract of the Chinese medicinal composition of example 1-5 is filtered through a 0.22 μm microporous membrane and stored in a refrigerator at-20 deg.C for further use.
3.2 preparation of Positive control
The acyclovir injection is prepared by using 2% DMSO cell maintenance solution, and the concentration is 50 mg/mL -1 (ii) a The ribavirin injection adopts stock solution with the concentration of 50 mg/mL -1 。
3.3 cell recovery and culture
And taking out the cryopreservation tube for preserving the cells from the liquid nitrogen tank, immediately putting the tube into warm water at 37-42 ℃ for thawing, and enabling the cells to rapidly pass through a freeze thawing process. Transferring the cell suspension into a centrifuge tube in a superclean bench for centrifugation, wherein the centrifuge has set parameters of the rotation speed of 800 r.min -1 And the time is 5 min. After centrifugation, the supernatant is aspirated, cell culture medium is added, the precipitated cells are blown gently through a pipette, the newly obtained cell suspension is transferred into a culture flask and placed in CO 2 Constant temperature incubator (culture conditions of 37 ℃ and 5% CO) 2 And relative humidity 75%), and subculturing after the cells are fully paved at the bottom of the bottle.
3.4 amplification of viruses
Collecting cells in exponential growth phase and in good growth state, discarding culture medium, washing with PBS for 3 times, adding virus solution 0.5mL, and placing in CO 2 Culturing in a constant temperature incubator, and slightly shaking the culture flask every 15min to make the virus liquid fully contact with the cells. With another cell control, 0.5mL of cell maintenance solution was added and the cells were cultured as above. After 1 hour of culture, 4.5mL of cell maintenance medium was added and the culture was continued. After 24h, microscopic examination is carried out, and the number of cells infected with the lesion>At 90%, the culture was stopped. Repeatedly freezing and thawing the cells for 3-4 times, transferring the virus liquid to a centrifuge tube for centrifugation, and setting the centrifuge with the set parameters of the rotation speed of 1000 r.min -1 Taking supernatant fluid, quantitatively subpackaging in a freezing tube, sealing for 5min,and storing in an ultra-low temperature refrigerator at-80 ℃ for later use.
3.5 determination of viral virulence
The amplified virus was diluted 10-fold with a cell maintenance medium, and the cells were sequentially plated in 96-well cell culture plates confluent with a monolayer of cells, with a total of 10 concentration gradients, and each concentration was repeated 3 times, with cell controls. The culture was carried out according to the method under "3.4". Observing the lesion under microscopic examination after 24h, and determining the number of cells infecting the lesion>At 90%, the culture was stopped. 10 μ L of 5 mg/mL was added to each well -1 The MTT dye solution is continuously cultured for 4h, the dye solution is removed by suction, 100 mu L DMSO is added into each hole, the mixture is decolored for L0 min in a dark place at room temperature, and the A value of the mixture at 490nm is measured by a microplate spectrophotometer.
3.6 determination of cytotoxicity of extract
Diluting the Chinese medicinal composition extractive solution with cell maintenance solution at 2 × ratio, setting 10 concentration gradients, sequentially inoculating into 96-well cell culture plate with confluent monolayer of cells, repeating each concentration for 3 times at 100 μ L per well, and setting cell control. The culture was carried out according to the method under "3.4". After 24h, the cell state was observed by microscopic examination, and the A value was measured by the method under the item "3.5".
3.7 determination of antiviral Activity of extract
From nontoxic concentration, the Chinese medicinal composition extractive solution is diluted by cell maintenance solution at 2 × ratio for 10 concentrations, added into 96-well cell culture plate with monolayer cells, 100 μ L per well, and then 100 μ L of virus solution is added, each concentration is repeated for 3 times, and positive drug (ribavirin or acyclovir) control group, virus control group and cell control group are provided. The culture was carried out according to the method under "3.4". After 24h, cytopathic effects were observed, and when > 90% of the viral controls appeared, the A value was determined as under "3.5".
4 results of the experiment
4.1 Virus virulence assay results
Calculating the half infection concentration (TCID) of the virus liquid according to Reed-Muench formula 50 ) The cell survival rate is x 100% for each group a/normal cell a; (ii) the rate of cell morbidity is 1-cell survival; distance ═ (above 50% variability-50%)/(above 50% variability-below 50% morbidity rate) x 100%; TCID 50 Results are shown in table 1 for anti (lg greater than 50% lesion rate virus dilution + distance).
TABLE 1.4 Virus TCIDs 50 Measurement results
4.2 measurement of cytotoxicity of extract solution
Calculating half Toxic Concentration (TC) of the drug by applying Reed-Muench formula 50 ) The results are shown in Table 2.
TABLE 2 TC of extracts versus 3 cells 50 Measurement result (mg. mL) -1 )
4.3 antiviral Activity assay results
Calculating half Effective Concentration (EC) of the drug by applying Reed-Muench formula 50 ) And Therapeutic Index (TI), EC 50 Not ═ Antilg (lg greater than 50% lesion rate virus dilution-specific distance)]X the initial concentration (C) of the test sample liquid medicine; TI-half Toxic Concentration (TC) 50 ) Effective concentration at half maximum (EC) 50 ) The results are shown in tables 3 and 4. The inhibition effect of the traditional Chinese medicine composition on the viruses is obviously better than that of common medicines of ribavirin and acyclovir.
TABLE 3 EC of extracts against 5 viruses 50 Measurement results (mg. mL) -1 )
TABLE 4 TI assay results of 5 viruses in the extract
Claims (7)
1. An antiviral traditional Chinese medicine composition is characterized by being prepared from the following raw material medicines in parts by weight: 1-25 parts of radix sophorae flavescentis, 1-25 parts of wild buckwheat rhizome leaves, 1-25 parts of liquorice, 1-25 parts of honeysuckle, 1-25 parts of scutellaria baicalensis and 1-25 parts of fructus forsythiae.
2. The antiviral traditional Chinese medicine composition as claimed in claim 1, which is prepared from the following raw materials in parts by weight: 1 part of radix sophorae flavescentis, 1 part of wild buckwheat rhizome and leaf, 1 part of liquorice, 1 part of honeysuckle, 1 part of scutellaria baicalensis and 1 part of forsythia suspensa.
3. The antiviral traditional Chinese medicine composition according to claim 1 or 2, wherein the traditional Chinese medicine composition is an aerosol, a decoction, a tablet, a capsule, a granule or a mixture.
4. The antiviral traditional Chinese medicine composition of claim 3, wherein the traditional Chinese medicine composition is an aerosol.
5. The use of a Chinese medicinal composition as claimed in any one of claims 1 to 4 in the preparation of an antiviral medicament.
6. Use of the Chinese medicinal composition of any one of claims 1 to 4 in the preparation of an anti-coronavirus medicament.
7. The use of the Chinese medicinal composition of any one of claims 1 to 4 in the preparation of a medicament for the prevention and treatment of respiratory tract infection caused by viruses as the main component.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110199421.1A CN114949044A (en) | 2021-02-23 | 2021-02-23 | Antiviral traditional Chinese medicine composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110199421.1A CN114949044A (en) | 2021-02-23 | 2021-02-23 | Antiviral traditional Chinese medicine composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114949044A true CN114949044A (en) | 2022-08-30 |
Family
ID=82954569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110199421.1A Pending CN114949044A (en) | 2021-02-23 | 2021-02-23 | Antiviral traditional Chinese medicine composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114949044A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107789517A (en) * | 2017-10-23 | 2018-03-13 | 上海凯宝药业股份有限公司 | A kind of Chinese medicine compound prescription antivirus defervescent and preparation method thereof |
| CN111643612A (en) * | 2020-05-06 | 2020-09-11 | 远见生物科技（上海）有限公司 | Traditional Chinese medicine composition for preventing and treating new coronavirus pneumonia and preparation method and application thereof |
-
2021
- 2021-02-23 CN CN202110199421.1A patent/CN114949044A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107789517A (en) * | 2017-10-23 | 2018-03-13 | 上海凯宝药业股份有限公司 | A kind of Chinese medicine compound prescription antivirus defervescent and preparation method thereof |
| CN111643612A (en) * | 2020-05-06 | 2020-09-11 | 远见生物科技（上海）有限公司 | Traditional Chinese medicine composition for preventing and treating new coronavirus pneumonia and preparation method and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| 刘德明等: "金荞麦地上部茎叶中多酚的提取工艺研究" * |
| 刘德明等: "金荞麦地上部茎叶中多酚的提取工艺研究", 《现代农业科技》 * |
| 郭文明: "连花清瘟胶囊联合金荞麦片治疗甲型Ｈ1Ｎ１流感疗效研究" * |
| 郭文明: "连花清瘟胶囊联合金荞麦片治疗甲型Ｈ1Ｎ１流感疗效研究", 《成都医学院学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113350439B (en) | Application of traditional Chinese medicine composition in preparation of antiviral drugs | |
| CN102000156A (en) | Traditional Chinese medicine compound preparation for treating cold, influenza and upper respiratory tract infection | |
| CN108686045B (en) | Callicarpa nudiflora composition and application thereof in treating pharyngitis | |
| CN102688332B (en) | A kind of Chinese medicine composition for the treatment of flu and preparation method thereof | |
| CN105998599A (en) | Traditional Chinese medicine composition for treating viral respiratory tract infection and preparation method thereof | |
| CN102641356B (en) | Traditional Chinese medicine composition for treating respiratory tract viral infectious diseases and preparation method thereof | |
| CN108524685B (en) | Composition for treating children herpangina and application thereof | |
| CN113616764B (en) | Antiviral traditional Chinese medicine composition and application thereof | |
| CN108403858B (en) | Callicarpa nudiflora extract composition for treating hand-foot-and-mouth disease and application thereof | |
| CN101584836B (en) | Detoxifying Chinese medicament and preparation method thereof | |
| CN102836200A (en) | Application of oil orange to preparation of anti-H1N1 flu medicament | |
| CN105343481A (en) | Application of influenza treating medicine composition in preparation of antiviral medicine | |
| CN111700998A (en) | Application of compound Chinese patent medicine in treating pneumonia COVID-19 infected by novel coronavirus | |
| CN102335373B (en) | Chinese medicinal composition for treating upper respiratory tract infection, and preparation method thereof | |
| CN111632116A (en) | Preparation method of traditional Chinese medicine preparation for resisting viral cold | |
| CN108186866B (en) | Application of golden scallop oral liquid in antivirus | |
| CN114949044A (en) | Antiviral traditional Chinese medicine composition and application thereof | |
| CN103356728B (en) | Pharmaceutical composition, preparation method thereof, preparations thereof and application thereof | |
| CN104027401B (en) | A kind of for child's antiviral, the SHUANGHUANLIAN drug regimen and preparation method thereof of heat clearing and inflammation relieving | |
| CN102028784B (en) | Traditional Chinese medicine composite with effects of reducing heat, relieving ache and resisting virus and preparation method thereof | |
| CN111743935A (en) | Traditional Chinese medicine composition for preventing and treating dengue fever virus and preparation method thereof | |
| CN115554347B (en) | Virus inhibitor and preparation method and application thereof | |
| CN108403795B (en) | Sishun cool beverage granules and preparation process thereof | |
| CN105940777B (en) | A kind of antiviral Chinese medicine composition | |
| CN101947278B (en) | Traditional Chinese medicine for treating viral lower respiratory tract infection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220830 |
|
| RJ01 | Rejection of invention patent application after publication |